May 23, 2011
By Basil "Bill" J. Lewris
Biotechnology and pharmaceutical companies are awaiting the FDA’s new regulations for implementing the 2010 Biologics Price Competition and Innovation Act (BPCIA), which will aim to provide an expedited approval framework for follow-on biologics. While industry leaders can only speculate on the content of those regulations, Finnegan partner Bill Lewris compares the key differences between the BPCIA and Hatch-Waxman Act, including what type of follow-on biologics the BPCIA contemplates, exclusivity periods, and the patent litigation process.
Conference
4th Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction Workshop
June 10-11, 2024
Basel
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Prosecution First Blog
May 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.